Private Label Partners, Inc.
FDA inspection history in Santa Ana, California, 2019 to 2025
- 2
- Form 483s
Every document, by year
- Form 483
2019: one Form 483; 2025: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2019One Form 483, at Santa Ana, California.
- 2025One Form 483, at Santa Ana, California.
- 2025The longest 483 on file: 7 observations over 10 pages at Santa Ana, California.
Cited most
Across all Private Label Partners observations on file
- 21 CFR 211.192Production record review2
- 21 CFR 211.84(d)(1)Testing and approval or rejection of components, drug product containers, and closures2
- 21 CFR 211.160(b)General requirements1
- 21 CFR 211.165(a)Testing and release for distribution1
- 21 CFR 211.166(a)Stability testing1
The complete Private Label Partners file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Santa Ana, California
Two Form 483s · 2019 to 2025 · 13 observations
Latest: Form 483, Jan 17, 2025 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2025-01-17 | 483 Form 483 | Santa Ana, California | 7 | $99 |
| 2019-09-13 | 483 Form 483 | Santa Ana, California | 6 | $99 |
Investigators on these documents
FEI number 3003350069 · most recent document Jan 17, 2025
About Private Label Partners, Inc.
How many FDA Form 483s has Private Label Partners, Inc. received?
FDA Intel has 2 Form 483s on file for Private Label Partners, Inc.; the most recent is dated Jan 17, 2025.
When was Private Label Partners, Inc. last inspected by FDA?
The most recent FDA inspection document on file for Private Label Partners, Inc. is a Form 483 dated Jan 17, 2025, for the site in Santa Ana, California.
What did FDA cite at Private Label Partners, Inc.?
The regulations cited most in the observations on file for Private Label Partners, Inc. are 21 CFR 211.192 (Production record review), 2 times; 21 CFR 211.84(d)(1) (Testing and approval or rejection of components, drug product containers, and closures), 2 times; 21 CFR 211.160(b) (General requirements), 1 time.